| Papers [1-15] of 100 :: [Page 1 of 7] | | Go to page : 1 2 3 4 5 6 7 —> | Search results on "ALZHEIMER DISEASE": |
|
|
Alzheimer?s Disease, 2005.
Examines Alzheimer's disease as a major medical problem for the new millennium.
3,215 words (approx. 12.9 pages), 17 sources, MLA, $ 92.95
»
Click here to show/hide summary
Abstract
As more and more people live longer, many suffer from senility and Alzheimer's disease. This paper discusses the stages of the disease and how medical science has advanced in its ability to diagnose Alzheimer's.
The paper also examines the future for this disease.
Introduction
The Definition of Alzheimer's Disease
The Genetics of Alzheimer's Disease
Stages of Alzheimer's Disease
Advances in Diagnosing Alzheimer's Disease
Predicting Alzheimer's Disease
Outlook for the Future
Footnotes
Bibliography
From the Paper
"Other researchers are focusing on the 'oxidative stress' and 'programmed cell death' parts of the puzzle. It is becoming clear that oxidative stress occurs in AD, but it is not yet clear whether oxidation actually causes the neuro-degeneration, or is simply another side effect of AD. Some scientists believe that oxidative stress is a relatively early event in the disease process. They argue that the aging brain is less able to defend itself against oxidative stress, and that this helps to explain why AD is a disease that primarily strikes older people. Researchers are working now to understand whether beta-amyloid initiates the oxidative damage in AD. Vitamin E and some of the other drugs that show promise against AD may have anti-oxidant properties."
| |
|
Alzheimer's Disease, 2007.
An examination of the causes and treatment options for Alzheimer's disease.
2,390 words (approx. 9.6 pages), 8 sources, MLA, $ 73.95
»
Click here to show/hide summary
Abstract
This paper provides an intensive exploration of Alzheimer's disease. The writer approaches it from the field of psychology and discusses the signs, symptoms, causes, risks, medications and treatment for the disease from a psychological perspective. The paper examines how Alzheimer's disease is being addressed and discusses the signs and symptoms that can indicate its onset. The paper analyzes the mental health issues that come with a diagnosis of the disease and treatments that dovetail with the current drugs being used. The paper concludes that, while Alzheimer's disease is still significantly stressful, there are great strides being made to combat its progression and effects.
Outline:
Introduction
What Is Alzheimer's?
History Of Alzheimer's Disease
History Of Alzheimer's Disease
Causes
Symptoms
Treatment
Conclusion
References
From the Paper
" Mood stabilizers have been found to be useful. Some of the drugs used to treat disease include "tacrine (Cognex), donepezil (Aricept), rivastigmine (Exelon), or galantamine (Razadyne, previously known as Reminyl) may help prevent some symptoms from becoming worse for a limited time. Another drug, memantine (Namenda), has been approved to treat moderate to severe AD, although it also is limited in its effects. Also, some medicines may help control behavioral symptoms of AD such as sleeplessness, agitation, wandering, anxiety, and depression. Treating these symptoms often makes patients more comfortable and makes their care easier for caregivers(Alzheimer's Disease Fact Sheet
http://www.nia.nih.gov/Alzheimers/Publications/adfact.htm).""
| |
|
Alzheimer's Disease, 2006.
A review of Alzheimer's disease, discussing the history, symptoms, treatments and issues related to the disease.
2,171 words (approx. 8.7 pages), 9 sources, MLA, $ 67.95
»
Click here to show/hide summary
Abstract
This paper takes an in-depth look at Alzheimer's disease, a degenerative brain disorder that was first identified in 1906 by Alois Alzheimer. This disease represents the single most prevalent form of brain disorders and is also the leading cause of dementia, affecting approximately 4.5 million people in the Untied States. The paper provides a brief overview of the disease, the symptoms, the diagnostic procedures and the treatment methods in order for us to gain a better understanding of this degenerative brain disorder.
Outline:
Introduction
Alzheimer's Disease
Early and Late onset Alzheimer's Disease
Symptoms of the Disease
Memory Loss and Language Disorder
Depression
Dyspraxia and Agnosia
Diagnosis
Tests for Cognitive Impairment
Positron Emission Topography
Major Causes of Alzheimer's Disease
Amyloid Plaques
NeuroFibrillary Tangles
Metal ions
Treatment Methods
Restoring Cholinergic Transmission
Anti-inflammatory Drugs
Conclusion
From the Paper
"Considerable reduction in cholinergic transmission is one of the primary causes for the loss of memory and other associated symptoms of Alzheimer's disease and other kinds of dementia. Hence pharmacological treatment for AD mainly revolves around rectifying this circulatory deficit within the brain. Compounds designed to enhance cholinergic transmission constitute an important part of the treatment plan. Acetylcholine the neurotransmitter of the brain is considerably broken down in-patients suffering from AD and other dementias. The underlying mechanism of the neurotransmitter can be simplified as follows. An electrical impulse generated passes along the nerve and when it reaches the end it triggers the release of chemical messengers known as neurotransmitters, which in turn diffuse along the synaptic cleft and react with the specific receptor sites on the organ. Activation at the receptor junction initiates a series of chemical reactions resulting in a specific biological response. "
| |
|
Alzheimer's Disease, 2009.
A look at alternative treatments for patients with Alzheimer's disease.
2,673 words (approx. 10.7 pages), 10 sources, APA, $ 80.95
»
Click here to show/hide summary
Abstract
This paper discusses alternative therapies for Alzheimer's disease patients and analyzes if these treatments work better on their own or in conjunction with the more traditional therapies that are more generally used in the treatment of Alzheimer's disease. Music, hand massages and a combination of both are looked at as therapies to treat the pain and mental confusion that Alzheimer disease patients often have. The paper also reviews literature and examines the different methods that are used in order to determine whether an elder that is suffering from Alzheimer's disease is in pain and if treatment for that pain is necessary.
From the Paper
" Likewise, the effectiveness of the treatment must also be considered, because no treatment, regardless of how safe it actually is, will be worthwhile if it does not work for the patient. This is part of the reason that there are different medications available that all treat the same thing, since not all patients respond in the same way to the same medication. The same is true of alternative therapies for Alzheimer's disease and the way that people with Alzheimer's are treated for pain and other issues that elderly people often develop in conjunction with the disease. Both safety and effectiveness have to be very strongly considered to find the right treatment for the patient in question, instead of treating everyone with Alzheimer's disease in the same way."
| |
|
Causes of Alzheimer's Disease, 2000.
A scientific paper on Alzheimer's disease. A discussion of the disease and an in depth look at its causes.
2,070 words (approx. 8.3 pages), 25 sources, $ 65.95
»
Click here to show/hide summary
Abstract
This review of Alzheimer?s disease (AD) focuses on the various causes of the disease. It is a compilation of material gathered from various scientific journals. The review begins by giving an introduction of AD followed by a discussion of various factors believed to cause AD, such as: amyloid plaques, neurofibrillary tangles, apolipoprotein E, and genetic factors. The author concludes by stressing the need for more research into the causes of AD.
Introduction
Overview of Alzheimer?s Disease
Pathological Causes of Alzheimer?s Disease
Amyloid Plaques
Neurofibrillary Tangles
Genetic Factors in the Development of Alzheimer?s Disease
Chromosome 19 and Apolipoprotein E
Other Genetic Factors
Presenilin
Conclusion
From the Paper
"Alzheimer?s disease (AD) is a neurodegenerative disorder characterized by progressive memory loss and dementia. The precise mechanisms that cause AD are still unknown, however, certain factors that predispose individuals to Alzheimer?s disease have been identified. Although no definitive cause has yet been discovered, this article reviews current research into various possible causes of AD, including the pathological causes, such as amyloid plaques and neurofibrillary tangles. Also the genetic factors that cause AD, such as apolipoprotein E (apoE) and presenilin gene."
| |
|
Dementia and Alzheimer's disease, 2007.
Discusses legislative care option recommendations for people with dementia and Alzheimer's disease.
1,260 words (approx. 5.0 pages), 5 sources, MLA, $ 42.95
»
Click here to show/hide summary
Abstract
This paper looks at legal recommendations for laws relating to care options for senior citizens with dementia and Alzheimer's disease from the perspective of a representative of a congressional district, which has a large senior population. The paper presents the background, statistics and costs relating to both of these conditions. The paper also reviews three care options and recommends a law that restricts the number of family members formally assigned to care for an elderly relative with Alzheimer's or dementia.
Table of Contents:
Problem Statement
Background
Dementia
Alzheimer's Disease
Landscape
Pertinent Statistical Data
Cost of Alzheimer's Disease
Options
Subsidize Specialized Diagnostic Testing for Alzheimer's Disease
Allow Limited Opportunities for Employment
Restrict the Number Of Family Members Formally Assigned to Care for an Elderly Relative with Alzheimer's or Dementia.
Recommendation
From the Paper
"Similar to the tenets of the Ryan White Act, the congressional district could allow certain individuals below the retirement age who are diagnosed with dementia and Alzheimer's disease closely-monitored employment opportunities. These should target specific areas of the Alzheimer's patient which have been least affected by the disease. This option will not only ease the financial burden associated with Alzheimer's but will also delay the individual's confinement to an elderly institution as he or she is still contributing significantly to society."
| |
|
Alzheimer's Disease, 2002.
A case control study of the risk factors for Alzheimer's Disease.
3,900 words (approx. 15.6 pages), 15 sources, $ 142.95
»
Click here to show/hide summary
Abstract
This is an epidemiological research paper on the "Case Control Study of Risk Factors for Alzheimer's Disease". It discusses the background of this disease, study design, survey instrument, risk factor involved, statistical analysis and potential biased information about this disease. This paper briefly reviews biological evidence suggesting that alcohol use may be associated with this disease. It also focuses on the evidence from epidemiological studies that link people's consumption of alcohol to whether they develop Alzheimer Disease, considers the influence of tobacco use on the relationship between alcohol use and Alzheimer's Disease, and examines the epidemiological evidence of the connection between alcohol consumption and types of cognitive impairment other than Alzheimer's disease.
| |
|
Alzheimer?s Disease and Primary Visitors, 2005.
An analysis of verbal and nonverbal behaviors between nursing home residents with Alzheimer's disease and their primary visitors.
4,586 words (approx. 18.3 pages), 59 sources, APA, $ 119.95
»
Click here to show/hide summary
Abstract
This research study attempts to examine the interactions between nursing home residents with Alzheimer's disease and their primary visitors who participated in a Family Visit Education Program. All of the visitors in the study were family members of nursing home residents with Alzheimer's disease and were participants in the Family Visit Education Program funded by the New York State Department of Health. The primary goal of the Family Visit Education Program (FVEP) is to improve the pattern of interactions during visits between family members and nursing home residents with Alzheimer's disease and thus to reduce problem behaviors within the residents. This study explores the family members' implementation of the training program components by reviewing videotapes made during the FVEP and by observing and classifying the behaviors of the residents' during the videotaped visits.
Introduction
Background
Research Goals
Significance
Literature Review
From the Paper
"The subjects in this current study were participants in the Family Visit Education Program (FVEP) developed by Toseland and McCallion (1995) of the Institute of Gerontology in Albany, New York. The FVEP research grant received funding from the New York State Department of Health. The participants in this study were nursing home residents with Alzheimer's disease, who lived in five nursing homes in the greater Albany, New York, area, and their relatives who visited them frequently. The FVEP visitor training protocol included education about the various stages of Alzheimer's disease, its associated verbal and nonverbal behaviors, new communication methods, and suggested activities to participate in with the residents. Some of the visits between the trained FVEP visitors and the residents were videotaped and these videotapes are the data source for the current study."
| |
|
Alzheimer Disease and Exercise, 2009.
This paper discusses the article "Exercise Plus Behavioral Management in Patients with Alzheimer Disease: A Randomized Controlled Trial," by Teri, L., Gibbons, L. E., McCurry, S. M., Logsdon, R. G., Buchner, D. M., Barlow, W. A., Kukull, W. A., LaCroix, A
873 words (approx. 3.5 pages), 1 source, MLA, $ 31.95
»
Click here to show/hide summary
Abstract
In this article, the writer analyzes the study by Teri, Gibbons, McCurry, Logsdon, Buchner, Barlow, Kukull, LaCroix, McCormick, and Larson, entitled "Exercise plus behavioral management in patients with Alzheimer Disease: A Randomized Controlled Trial," that was published in JAMA, 290(15): 2015-2022. The writer explains that the purpose of the study was to develop a home-based exercise program combined with caregiver training in behavioral management techniques. The writer notes that this home-based exercise program was designed to reduce functional dependence and delay institutionalization among patients with Alzheimer disease. Older adults can benefit from exercise through the improvement of cardiovascular function, flexibility, balance, and strength. Exercise has also been demonstrated by several studies to reduce depression among elderly patients, as well as alleviate depression of patients with dementia. The writer concludes that this study has promising potential in the management of Alzheimer disease.
From the Paper
"A total of 153 patients and their corresponding caregivers were randomly selected from an ongoing, community-based Alzheimer disease patient registry and through referrals from physician practices. The study, from enrollment to the end of follow-up, occurred from June 1994 to April 1999. Written consent was obtained from both caregiver and patient. All patients underwent comprehensive evaluation by a geriatrician, neurologist, psychologist, and epidemiologist, nurse, and research staff. The caregivers were spouses or adults who lived with or spend at least 4 hours with these patients. Their ages ranged from 24 to 91 years old, and 70% were female. Eighty percent of the caregivers were spouses.
"Patient-caregiver groups were randomly assigned to the RDAD program or routine medical care. At first, patient and caregiver were seen in their own homes by experienced health professionals for 12 hour-long sessions at 2 sessions per week for the first three weeks, then weekly sessions for 4 weeks, and then twice a month. This was to ensure proper training of caregivers at home. Follow-up was done three times over the next 3 months. "
| |
|
Alzheimer 's Disease Medication, 2008.
Discuses the Exelon patch and rivastigmine, a medication used for the treatment of Alzheimer's disease.
1,175 words (approx. 4.7 pages), 7 sources, APA, $ 40.95
»
Click here to show/hide summary
Abstract
This paper explains that the Exelon patch is a means of dosing a patient with mild to moderate Alzheimer's disease with rivastigmine, a cholinesterase inhibitor. The author stresses that, based on clinical studies, rivastigmine is not recommended in the treatment of patients with mild to moderately severe Alzheimer's disease. The paper compares the physiology and use of this medication for Alzheimer's disease and Parkinson's dementia.
Table of Contents:
Introduction
Difference between Use for Alzheimer's vs. Parkinson's Dementia
Physiologically Difference of these Two Dementias
Rivastigmine
Advantage of a "Patch
"Moderate" Dementia
Implications of the Health Issue
Circumstances Contributed to this Current Health Care Issue
Implications for Dental Hygienist
From the Paper
"Treating a patient with Alzheimer's disease with rivastigmine may create false hopes in the caregiver's mind, which affects the economic, social, lifestyle, legal, political, medical and ethical considerations of both patient and caregiver. If the drug, which seems to promise delay of full-time care of a progressive disease, does not deliver this delay, the expectations and therefore the planning of future activities and care are deeply affected. Liability increases on the part of diagnostician, the one prescribing the drug and the administrator."
| |
|
Alzheimer's Disease, 2001.
An overview of Alzheimer's disease and a look at the research and studies being conducted as well its the prognosis for the future.
1,633 words (approx. 6.5 pages), 10 sources, MLA, $ 53.95
»
Click here to show/hide summary
Abstract
This paper discusses how Alzheimer's disease is a progressive and debilitating disease affecting an estimated four million people in the United States. It looks at how it begins slowly and progresses over time and how symptoms may include memory loss, confusion, problems with thinking and learning and behavioral changes. It also discusses how, at this time, no known cure for Alzheimer's Disease exists and how researchers are testing a great number and variety of substances in hopes of finding ways to ease, slow, and eventually prevent Alzheimer's disease.
From the Paper
"The symptoms of Alzheimer's Disease are caused by the destruction of brain cells. These symptoms include problems with memory and in later stages impairments in language and reason. Alzheimer's Disease progresses at varying speeds and symptoms may differ among patients. Characterizing features include its gradual onset, progressive decline in cognitive function, difficulty in learning and retaining new information, and finally disorientation and impaired judgement. In the later stages, there is a marked change in behavior and mood, leading to delusions, aggression, and wandering. "
| |
|
Alzheimer's Disease, 2006.
This paper describes Alzheimer's disease and some suspected causes.
1,497 words (approx. 6.0 pages), 6 sources, APA, $ 49.95
»
Click here to show/hide summary
Abstract
This paper describes the symptoms of Alzheimer's disease and examines possible causes for the condition. A description of the discovery of the disease is followed by a discussion of its symptoms. A significant portion of the paper is a review of current literature regarding causes of Alzheimer's disease. The paper concludes with a description of populations at risk of developing Alzheimer's disease.
Table of Contents
AD History
Suspected Causes of AD
Is AD Contagious?
Is it Caused by Something we Eat?
Other Risk Factors
Conclusion
From the Paper
"Proteins, not necessarily those consumed but rather those made in the body, have also formed a basis for AD research. Pathologist George C. Glenner, in 1983, examined the molecular structure of [beta]-amuloid, a structure that constitutes the tip of the plaques present in AD, and discovered that the concentration of these amyloids is particularly high, appearing like strips of sticky substance spilled on a floor and gumming up the works (Odle, 2003). Since Glenner's work, new research indicates that [beta]-amyloid is toxic to neurons, and could therefore easily lead to cell destruction."
| |
|
MCI and Alzheimer's Disease, 2007.
This paper discusses the background of mild cognitive impairment and its relationship to Alzheimer's disease.
882 words (approx. 3.5 pages), 5 sources, MLA, $ 31.95
»
Click here to show/hide summary
Abstract
The paper explains that Mild Cognitive Impairment (MCI) is a fairly new term to the medical community. The paper relates that most healthcare professionals use it to describe "people who have some problems with their memory but do not actually have dementia." The paper discusses how studies indicate MCI can predict Alzheimer's. The paper explains that as research progresses, a new understanding of Alzheimer's disease and its predictors could hopefully allow treatment and longevity for victims of this disease. The paper relates that for those continuing to suffer from the disease, new designs in assisted living and Alzheimer's facilities can facilitate treatment, a better quality of life and increased involvement in eventually discovering a cure for Alzheimer's disease.
From the Paper
"This condition is not a disease, and not everyone who has it develops Alzheimer's disease. However, many studies indicate MCI can predict Alzheimer's and many individuals diagnosed with MCI do go on to develop Alzheimer's within a few years. The Alzheimer's Society of Great Britain notes, "In studies carried out in memory clinics, 10-15 per cent of people with MCI went on to develop dementia in each year that the research results were followed up" (Editors). In other words, about 50 percent of MCI sufferers developed Alzheimer's within three to five years of their diagnosis (Sherman 1)."
| |
|
Alzheimer's Disease, 2002.
A critical review of a research article examining the brain regions which are affected in Alzheimer's Disease.
4,299 words (approx. 17.2 pages), 47 sources, MLA, $ 113.95
»
Click here to show/hide summary
Abstract
This paper examines the research article "Cerebrospinal Fluid Beta-Amyloid(1-42) in Alzheimer Disease: Differences Between Early- and Late-Onset Alzheimer disease and Stability During the Course of Disease" by Teipel, Hampel, Pietrini, Alexander, Horwitz, Daley, Moller, Schapiro and Rapoport (1999) which investigates region-specific corpus callosum atrophy in relation to the pattern of cortical glucose metabolism in Alzheimer. It shows how the reviewed material examines the authors' primary research questions, their justification for the study, the general methods and main findings. The review ends with a statement of whether confidence can be placed in the findings.
From the Paper
"Methods involved a two-group comparison of AD patients (N=12) and healthy controls (N=15). It is noted that controls were volunteers but no mention is made of how any of the subjects were recruited into the study. Further, AD patients were not authenticated as having the disease; rather it was noted that some patients were suspected of "possibly" having the condition while others were viewed as "probably" having AD. Tests of cognitive functioning were administered to the AD patients showing that they ranged in degree of dementia from mild to severe."
| |
|
Alzheimer's Disease, 2007.
This paper considers the medical and social aspects of Alzheimer's disease.
1,912 words (approx. 7.6 pages), 14 sources, MLA, $ 61.95
»
Click here to show/hide summary
Abstract
The paper relates that Alzheimer's disease typically afflicts patients during the later years of their lives and is most commonly associated with a general loss of cognitive function. The paper discusses the prevalence of Alzheimer's and its increasing profile during the 1990s that led scientists to dub it the "disease of the 20th century." The paper illustrates how Alzheimer's can place a terrible burden on a patient's loved ones, who are forced to watch the patient's slow mental decline. The paper also notes that the cost of Alzheimer's to American society is significant. The paper concludes that science will have to commit tremendous intellectual and financial resources to developing a cure for Alzheimer's, as the disease is expected to greatly proliferate over the next several years.
From the Paper
"A number of things occur in the brain that cause a person to develop Alzheimer's symptoms. Many Alzheimer's patients experience a sharp decrease in the production of acetylcholine, a key neurotransmitter, and over-production of the protein B-amyloid, which can cause obstructive neuritic plaques to form (Alzheimer's disease, No date). Alzheimer's patients also may experience brain deterioration related to aging, such as neuron or snynaptic loss, which can impair cognitive and neurological function."
|
|
|
